Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
People with systemic lupus erythematosus (SLE) often face irreversible organ damage due to uncontrolled disease activity, frequent disease flares, and long-term glucocorticoid treatment. A recent ...
For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients receiving standard of ...
AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus erythematosus (SLE) after claiming FDA approval for the drug as an add-on therapy for adults with the ...
The U.S. Food and Drug Administration (FDA) approved anifrolumab in 2021 for treatment of systemic lupus erythematosus, the most common form of lupus. Anifrolumab Is a monoclonal antibody that ...
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
HealthDay on MSN1mon
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback